|
Petersen EE. Infektionen in Gynäkologie und Geburtshilfe.
Georg Thieme Verlag Stuttgart New York 1988
Petersen EE. Infektionsdiagnostik in der Praxis. Gynäkologe
1996; 29:138-143
Clad A. Sexuell übertragbare Infektionen. Gynäkologe
1997; 30: 370-380
Hoyme UB. Die Klinik der entzündlichen Erkrankungen
des Uterus und der Adnexe. Gynäkologe 1997; 30: 277-285
Ghiatas AA. The spectrum of pelvic inflammatory disease.
Eur Radiol. 2004 Jan 29
Hoyme UB. Aktuelles Konzept der Pathogenese, Diagnostik
und Therapie der Adnexitis. Gynäkologe 1996; 29: 88-95
Adimora AA, Schoenbach VJ, Bonas DM, Martinson FEA, Donaldson
KH, Stancil TR. Concurrent Sexual Partnerships among Women
in the United States. Epidemiology 2002; 13 (3): 320-327
Wachter I. Jugendgynäkologie: Genitalinfektionen.
TW Gynäkologie 1996; 9: 663-664
Wissenbacher ER. Fluorpraktikum, medifact mrugalla
verlags KG 1993
Rassner G. Atlas der Dermatologie und Venerologie,
Urban & Schwarzenberg München Wien Baltimore 1978
Wiesmann E. Medizinische Mikrobiologie. Georg Thieme
Verlag Stuttgart, 1978
Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C.
Geburtshilfe und Gynäkologie, 3. Auflage. Springer Verlag
Berlin Heidelberg New York Paris Tokyo Hong Kong 1989
Müller H, Friese K. Entzündliche Erkrankungen der
Vulva und Vagina. Gynäkologe 2002; 35: 892-909
Blake DR. Adolescent Sexually Transmitted Diseases:
Recent Developments. Curr Infect Dis Rep. 2004; 6(2): 141-148.
Arbeitsgemeinschaft für Infektionen und Infektionsimmunologie
in der Gynäkologie und Geburtshilfe. Leitlinie Vulvovaginal-Kandidose.
Frauenarzt 2003; 44 (7):781-785
Nyirjesy P, Sobel JD. Vulvovaginal candidiasis. Obstet
Gynecol Clin North Am. 2003; 30 (4):671-84.
Rylander E, Berglund AL, Krassny C, Petrini B. Vulvovaginal
candida in a young sexually active population: prevalence
and association with oro-genital sex and frequent pain at
intercourse. Sex Transm Infect. 2004; 80 (1): 54-7.
Reed BD, Zazove P, Pierson CL, Gorenflo DW, Horrocks J.
Candida transmission and sexual behaviors as risks for a repeat
episode of Candida vulvovaginitis. J Womens Health 2003; 12(10):
979-89.
Donders GGG, Prenen H, Verbeke G, Reybrouck R. Impaired
tolerance for glucose in women with reccurent vaginal candidiasis.
Am J Obstet Gynecol 2002; Vol 187 (4): 989-993
Vine MF, Stein L, Weigle K. Gender differences in
response to the multitest CMI skin test in the general population.
Ann Allergy Asthma Immunol. 2000; 84 (4):445-50.
Beier-Holgersen R, Brandstrup B. Influence of early
postoperative enteral nutrition versus placebo on cell-mediated
immunity, as measured with the Multitest CMI. Scand J Gastroenterol.
1999; 34 (1):98-102.
Bardare M, Armenio L, Businco L, Cavagni G, De Martino
M, Duse M, Masi M, Monafo V, Pietrogrande MC, Tovo P, et al.
Screening for delayed-hypersensitivity in Italian children:
multicentric study by multitest skin testing. Eur J Pediatr.
1990; 150 (1):37-9.
Mendling W. Die Trichomoniasis. Frauenarzt 2002; 43
(1):40-42
Swygard H, Sena AC, Hobbs MM, Cohen MS. Trichomoniasis:
clinical manifestations, diagnosis and management. Sex Transm
Infect. 2004; 80 (2):91-5.
Soper D. Trichomoniasis: under control or undercontrolled?
Am J Obstet Gynecol. 2004; 190(1):281-90
Ness RB, Hillier SL, Richter HE, Soper DE, Stamm C, McGregor
J, Bass DC, Sweet RL, Rice P. Douching in Relation to
Bacterial Vaginosis, Lactobacilli, and Facultative Bacteria
in the Vagina. Obstet Gynecol 2002; Vol 100 (4): 765-772
Wilson J. Managing recurrent bacterial vaginosis.
Sex Transm Infect. 2004; 80 (1):8-11.
Hausterin UF; Hoyme UB, Mendling W, Petzold D, Wutzler
P. Herpes genitalis die unterschätzte Erkrankung? Beilage
in Der Gynäkologe 1997; Band 30 Heft 2
Hoyme UB. Aktuelle Aspekte der Herpesinfektion. T&E
Gynäkologie, 1998; 195-199
Crumpacker CS. Use of antiviral drugs to prevent herpesvirus
transmission. N Engl J Med. 2004; 350(1):67-8.
Villa A, Berman B. Genital herpes infection: beyond
a clinical diagnosis. Skinmed. 2003; 2 (2):108-12.
Brentjens MH, Yeung-Yue KA, Lee PC, Tyring SK. Recurrent
genital herpes treatments and their impact on quality of life.
Pharmacoeconomics. 2003; 21 (12): 853-63.
Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG.
Effect of Nonoxynol-9 Gel on urogenital Gonorrhea and chlamydial
Infection. JAMA 2002; Vol 287 (9): 1117-1122
Dan M. The return of gonorrhea. Isr Med Assoc J. 2004;
6(3):164-166
Jungmann E, Ison C, Martin IM, Fenton KA. Gonorrhoea
in young heterosexuals attending urban STD clinics in Britain:
a cross-sectional survey. Int J STD AIDS. 2004; 15(4):243-248
Feldmann HU. Chlamydien Infektion: Sexuell übertragbare
Bakterien können schwerwiegende Krankheiten verursachen. gyne
topics 1997; Nummer 7
Petersen EE, Clad A. Genitale Chlamydien-Infektionen.Dt
Ärztebl 1995; 92: A-277-282
Rothman KJ, Lanza L, Lal A, Peskin EG, Dreyer NA.
Incidence of Pelvic Inflammatory Disease among Women Treated
for Gonorrhea or Chlamydia. Pharmacoepidemiol Drug Saf. 1996;
5(6):409-14.
Hoc S. Azithromycin - ein ungewöhnliches Antibiotikum
gegen STD. Beilage in Der Urologe, 1996; Band 36; Heft 4
Zenilman JM. Chlamydia and Cervical Cancer. A Real
Association? JAMA 2001; 285 (1) Editorial
Koskeal P, Anttila T, Bjorge T, Brunsvig A et al.
Chlamydia trachomatis infection as a risk factor for invasive
cervical cancer. Int J Cancer 2000; 85 (1): 35-39
Antilla T; Saikku P, Koskela P, Bloigu A et al. Serotypes
of Chlamydia trachomatis and Risk for Development of Cervical
Squamous Cell Carcinoma. JAMA 2001; Vol 285 (1):47-51
Expertengremium der Deutschen STD-Gesellschaft. Condylomata
acuminata und andere HPV-assoziirte Krankheitsbilder des Genitale
und der Harnröhre. Leitlinie der Deutschen STD-Gesellschaft,
Juni 2000
Kahn JA, Rosenthal SL, Succop PA, Ho GYF, Burk RD.
Mediators of the Association Between Age of First Sexual Intercourse
and Subsequent Human Papilomavirus Infection. Pediatrics 2002,
Vol 109 (1): e5
Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior
P. et al. Natural history of cervical human papillomavirus
infection in young women: a longitudinal cohort study. Lancet
2001; 357 (9271): 1831-6
Morrison EA; Gammon MD, Goldberg GL, Vermund SH, Burk
RD. Pregnancy and cervical infection with human papillomaviruses.
Int J Gynecol Obstet 1996; 54 (2): 125-30
Rosen AC, Klein M, Reckendorfer H, Metzenbauer M, Puchhammer
E, Hafner E, Reiner a, Phillipp K. Die Dynamik zervikaler
HPV-Infektionen während der Schwangerschaft. Geb Fra 2000;
1: 60
Webster K, Taylor A, Gaston K. Oestrogen and progesterone
increase the levels of apoptosis induced by the human papillomavirus
type 16 E2 and E7 proteins. J Gen Virol 2001; 82: 201-213
Schoell WMJ, Winter R. Imiquimod zur Therapie genitaler
genitaler Kondylome: Klinische Ergebnisse, Wirkungsmechanismus
und Zukunftsperspektiven für die Immuntherapie des Zervixkarzinoms.
Geb Fra 2001; 17.11.03
Castellsague X, Bosch X, Munoz N, Meijer C, Shah KV et
al. Male Circumcision, Penile Human Papillomavirus Infection,
and Cervical Cancer in Female Partners. N Engl J Med 2002;
346: 1105-1112
Manning SD, Tallman P, Baker CJ, Gillespie B, Marrs CF,
Foxman B. Determinants of Co-Colonization with Group B
Streptococcus among Heterosexual Colelge Couples. Epidemiology
2002; 13 (5): 533-539
Kumar R, Agrawal B. Novel treatment options for hepatitis
B virus infection. Curr Opin Investig Drugs. 2004 Feb;5(2):171-178
Chen CH, Eng HL, Lee CM, Kuo FY, Lu SN, Huang CM, Tung
HD, Chen CL, Changchien CS. Correlations between hepatitis
B virus genotype and cirrhotic or non-cirrhotic hepatoma.
Hepatogastroenterology. 2004; 51 (56): 552-5.
Desai S, Cohen S, Khatamee M, Leiter E. Ureaplasma
urealyticum (T-mycoplasma) infection: does it have a role
in male infertility? J Urol. 1980; 124 (4):469-71.
Fenkci V, Yilmazer M, Aktepe OC. Have Ureaplasma urealyticum
and Mycoplasma hominis infections any significant effect on
women fertility? Infez Med. 2002; 10(4):220-3.
Ladipo OA, Osoba AO. T-mycoplasma and reproductive
failure. Infertility. 1979; (2) 2:135-45.
Schulte-Uebbing C. Umweltbedingte Frauenkrankheiten.
Sonntag Verlag Stuttgart 1995
Uehling DT, Hopkins WJ, Beierle LM, Kryger JV, Heisey
DM. Vaginal mucosal immunization for recurrent urinary
tract infection: extended phase II clinical trial. J Infect
Dis 2001; 183 (1): S81-3
Reid G. Probiotic agents to protect the urogenital
tract against infection. Am J Clin Nutr 2001; Vol 73 (2):
437S-443S
Reid G, Bruce AW, Fraser N, Heinemann C, Owen J, Henning
B. Oral probiotic can resolve urogenital infections. FEMS
Immunol Med Microbiol 2001; Vol 30 (1): 49-52
Reid G. Probiotic Therapy and Functional Foods for
Prevention of Urinary Tract Infections: State of the Art and
Science. Curr Infect Dis Rep 2000; Vol 2 (6): 518-522
Infante JR, Torres-Avisbal M, Pinel P, Vallejo JA, Peran
F. et al. Catecholamine levels in practitioners of the
transcendental meditation technique. Physiol Behav 2001; 72
(1-2): 141-146
Myss C. Anatomija duha, Dvostruka Duga Èakovec, 1999
Epstein DM. 12 stupnjeva iscjeljenja, Dvostruka duga
Èakovec, 1998
Mindell E. Vitaminska biblija za 21. stoljeæe, Mozaik
knjiga Zagreb, 2001
Null G. Enciklopedija za ¾ene, Barka Zagreb 1999
Atkins R. Vita-hranjiva dr. Atkinsa, VBZ Zagreb, 1999
Brennan BA. Svjetlost se raða. Put ka samoiscjeljenju.
Barka Zagreb 1997
Northrup C. ®ensko tijelo, ¾enska mudrost, Biovega
doo Zagreb, 2000
Kuhn H, Jung-Hoffmann C. Kontrazeption. Ferdinand
Enke Verlag Stuttgart 1996
Neulen J. Kontrazeption: Welche Methoden stehen zur
Verfügung? Frauenarzt 2003; 44(3):294-298
Attar E, Gokdemirel S, Serdaroglu H, Coskun A. Natural
contraception using the Billings ovulation method. Eur J Contracept
Reprod Health Care. 2002; 7(2):96-9.
Shivanandan M. Natural family planning: folly or fulfillment?
Marriage Fam Living. 1976; 58(10):2-5.
France JT. The ovulation method of family planning.
IPPF Med Bull. 1973; 7 (3):2-3.
Stagge P. Sicherheit von Kondomen. TW Gynäkologie
1996; 9: 438-446
Nutz M. Das Diaphragma als sichere Alternative. hautnah
gynäkologie + geburtshilfe 1997; 4: 163-165
Bitzer J. Kontrazeption bei Drogenabhängigen. T&E
Gynäkologie 1998; 210-215
Felberbaum R, Diedrich K. Orale Kontrazeptiva - Vorteile
und Risiken. Gynäkologe, 1997; 30: 305-313
Braendle W. Zur laufenden Pillendiskussion: Sorgfältige
Familienanamnese notwendig. hautnah gynäkologie + geburtshilfe
1997; 1: 16-19
Geurts TBP, Goorisen EM, Sitsen JMA. Übersicht über
Arzneimittelinteraktionen mit oralen Kontrazepiva. The Parthenon
Publishing Group London Casterton new York, 1994
Kemmeren JM, Algra A, Grobbee DE. Effect of second
and third generation oral contraceptives on lipid metabolism
in the absence or presence of the factor V Leiden mutation.
J Int Med 2001; 250 (5):441-448
Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism
with cyproterone or levonorgestrel contraceptives. Lancet
2001; Vol 358 (9291):1427-29
Gris JC, Jamin C. Benifla JL, Quere I, Madelenat P, Mares
P. APC resistance and third-generation oral contraceptives:
Acquired resistance to activated protein C, oral contraceptives
and the risk of thromboembolic disease. Hum Reprod 2001; 16
(1):3-8
Karck U, Breckwoldt M. Niedrig dosierte orale Kontrazeptiva
und Knochendichte. Therapeutische Umschau, Band 58, 2001;
Verlag Hans Huber, Bern
Kemmeren JM, Algra A, Grobbe DE. Third generation
oral contraceptives and risk of venous thrombosis: meta-analysis.
BMJ 2001; 323 (7305): 131-134
Eisenburg J. Lebertumoren unter Kontrazeptiva. Dt
Ärtztebl 88; 1991; Heft 18: A1569-A1578
Scalori A, Tavani A, Gallus S, La Vecchia C, Colombo M.
Oral contraceptives and the risk of focal nodular hyperplasia
of the liver: A case-control study. Am J Obstet Gynecol 2002,
Vol 186 (2): 195-197
Gram I, Macaluso M, Stalsberg H. Oral contraceptive
use and the incidence of cervical intraepithelial neoplasia.
Am J Obstet Gynecol 1992; 167: 40-44
Coker AL, McCann MF, Hulka BS, Walton LA. Oral contraceptive
use and cervical intraepithelial neoplasia. J Clin Epidemiol
1992; Vol 45 No 10: 1111-1118
Delgado-Rodrigues, Sillero-Arenas M, Martin-Moreno JM,
Galvez-Vargs R. Oral contraceptives and cancer of the
cervix uteri. Acta Obstet Gynecol Scand 1992; 71: 368-376
Rushton L, Jones DR. Oral contraceptive use and breast
cancer risk: a meta-analysis of variations with age at diagnosis,
parity and total duration of oral contraceptive use. Br J
Obstet Gynaecol 1992; Vol 99: 239-246.
Wingo P; Lee NC, Ory HW, Beral V; Pereson HB, Rhodes P.
Age-Specific Differences in the Relationship between Oral
Contraceptive Use and Breast Cancer. Cancer suppl 1993; Vol
71 (4):1506-1516
Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG,
Rodriguez GC. Impact of Progestin and Estrogen Potency
in Oral Contraceptives on Ovarian Cancer Risk. J Natl Cancer
Inst 2002; Vol 94 (1): 32-38
Smallwood GH; Meador ML; Lenihan JP. Shangolf GA et al.
Efficacy and safety of a transdermal contraceptives system
Obstet Gynecol 2001; 98 (5 PT 1): 799-805
Sicat BL. Ortho Evra, a new contraceptive patch. Pharmacotherapy.
2003;23(4):472-80.
Zite NB, Shulman LP. New options in contraception
for teenagers. Curr Opin Obstet Gynecol. 2003; 15(5):385-9.
Kuhl H. Neue Gestagene - ihre Vor- und Nachteile.
Therapeutische Umschau, Band 58; Verlag Hans Huber Bern, 2001
Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM.
Injectable Hormone Contraception and Bone Density: Results
from s Prospective Study. Epidemiology 2002; Vol 13 (5): 581-587
Pankratz-Hauer M, Pauli F. Implanon: Lokalisation
und Entfernung. Frauenarzt 2003; 44 (3): 310-313
Edwards JE, Moore A. Implanon: a review of clinical
studies. British Journal of Family Planning 1999; 4:3-16
Pasquale SA, Sinofsky FE. Pharmacology of Implanon:
A Two Year Study Evaluating Absorption, Stabilization of Levels
and Elimination Rate. ASRM Meeting 1996
Koch UJ, Tauber P, Wagner H. Empfehlungen des Arbeitskreises
"Intrauterinpessare" Nourypharma GmbH Oberschleißheim
1998.
Winkler UH. Vasovagale Reaktionen beim Legen eines
Intrauterinpessars. gynäkol.prax. 1996; 20: 127-128
Nagrani R, Bowen-Simpkins P, Barrington JW. Can the
levonorgestrel intrauterine system replace surgical treatment
for the management of menorrhagia? Br J Obstet Gynaecol 2002,
Vol. 109 (3): 345-347
ACOG practice bulletin Nr 46. Vorteile und Risiken
der Sterilisation. Frauenarzt 2004; 45 (3):204-212
Runnebaum B. Kontrazeption in den Wechseljahren der
Frau. hautnah gynäkologie + geburtshilfe 1997; 1: 20-21
Beller FK. Notfall Kontrazeption. Eine Neubesinnung
der Morning after Pill. Seminar des Frauenarztes, Frauenarzt
1998; 109-113
Spycher Ch, Bigler G. Postokoitale Notfall-Kontrazeption.
Therapeutische Umschau, Band 58; Verlag Hans Huber Bern, 2001
ACOG practice bulletin. Emergency oral contraception.
Number 25. Int J Gynecol Obstet 2002; Vol 78: 191-198
David M, Hamann C, Lichtenegger W. Nitroglycerin-Pflaster
als Therapieoption bei schwerer Dysmenorrhö: Resultate einer
In vitro-Untersuchung und klinische Erfahrungen. Geb Fra 2000;
10:489
Sultan C, Jeandel C, Paris F, Trimeche S. Adolescent
Dysmenorrhoea. Endocr. Dev 2003; 7:140-147
Benedetto C. Eicosanoids in Primary Dysmenorrhea,
Endometriosis and Menstrual Migraines. 1989; 3(1):71-94
Harel Z. Cyclooxygenase-2 specific inhibitors in the
treatment of dysmenorrhea. J Pediatr Adolesc Gynecol. 2004;
17(2):75-9.
Harel Z. Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation
with Omega-3-Fatty Acids in the Management of Dysmenorrhea
in Adolescents. Am J Obstet Gynecol 1996; 174:1335-1338
Weissman AM, Hartz AJ, Hansen MD, Johnson SR . The
natural history of primary dysmenorrhoea: a longitudinal study.
BJOG. 2004; 111 (4):345-352.
König D, Berg A, Keul J, Schäfer W, Zahradnik HP.
Prämenstruelles Syndrom, Migräne und Präklampsie: Ist die
Fettsäurequalität mitentscheidend? T&E Gynäkologie 1998;
(11): 70-76
Kouri EM, Halbreich U. Hormonal treatments for premenstrual
syndrome. Drugs Today (Barc). 1998; 34 (7):603-10.
Michalitsch CM. Das prämenstruelle Syndrom als Leber-Qi-Stagnation.
Ärzte Woche 2002; 16: 23.
Huang KL, Tsai SJ. St. John's wort (Hypericum perforatum)
as a treatment for premenstrual dysphoric disorder: case report.
Int J Psychiatry Med. 2003; 33 (3):295-297
Abraham GE. Nutritional Factors in the Etiology of
the Premenstrual Tension Syndrom. J Reprod Med 1983; 28 (7):446-464
Cohen LS, Miner C, Brown EW et al. Premenstrual Daily
Fluoxetine for Premenstrual Dysphoric disorder: A Placebo-controlled,
Clinical Trial using Computerized Diaries. Obstet Gynecol
2002; Vol 100 (3): 435-444
Gould D. Benign ovarian neoplasms. Nurs Stand. 2004;
18(17):45-52
Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio
RJ, van Nagell JR Jr. Risk of malignancy in unilocular
ovarian cystic tumors less than 10 centimeters in diameter.
Obstet Gynecol. 2003; 102 (3):594-9.
Horn Ross P, Whitemore AS; Harris R; Itnyre J. and the
Collaborative Ovarian Cancer Group. Characteristics Relating
to Ovarian Cancer Risk: Colaborative Analysis of 12 US Case-Control
Studies. CI. Nonepithelial Cancers among Adults. Epidemiology
1992; 3: 490-495
Holt VL, Daling JR; McKnight B, Moore D, Stergachis A,
Weiss NS. Functional Ovarian Cysts in Relation to the
Use of Monophasic and Triphasic Oral Contraceptives. Obstet
Gynecol 1992; 79:529-33
Lanes SF; Birmann B; Walker AM, Singer S. Oral contraceptive
type and functional ovarian cysts. Am J Obstet Gynecol 1992;
166: 956-961
Lindheim SR, Adsuar N, Kushner DM, Pritts EA, Olive DL.
Sonohysterography: a valuable tool in evaluating the female
pelvis. Obstet Gynecol Surv. 2003; 58 (11):770-84.
Lippman SA, Warner M, Samuels S, Olive D, Vercellini P,
Eskenazi B. Uterine fibroids and gynecologic pain symptoms
in a population-based study. Fertil Steril. 2003; 80 (6):1488-94.
Bradley JP:
Quick Review: Uterine Fibroids.
The Internet J Gyn Obstet 2002; (1): 2
Nass Duce M, Oz U, Ozer C, Yildiz A, Apaydin FD, Cil F.
Diagnostic value of sonohysterography in the evaluation of
submucosal fibroids and endometrial polyps. Aust N Z J Obstet
Gynaecol. 2003; 43 (6):448-52.
Elser DM; Fedirko B, Silver M. Uterine leiomyomata
are a marker for systemic hypertension. Obstet Gynecol 2001;
97 (4 Suppl 1): S23
Hilgarth M, Szalay L. Farbatlas der gynäkologische
Zytodiagnostik. Hans Marseille Verlag München, 1986
Soost Hans-Jürgen, Baur S. Gynäkologische Zytodiagnostik.
Georg Thieme Verlag 1990
Quddus MR, Sung CJ, Eklund CM, Reilly ME, Steinhoff MM.
ASC:SIL ratio following implementation of the 2001 Bethesda
System. Diagn Cytopathol. 2004; 30 (4):240-2.
Quddus MSolomon
D et al. The 2001 Bethesda
system. Terminology for reporting results of cervical cytology.
JAMA 2002; 287:2114-9
Wright TC et al. 2001 consensus guidelines for the management
of women with cervical cytological abnormalities. JAMA 2002M
287;2120-9
Stoler MH. New Bethesda terminology and evidence-based
management guidelines for cervical cytology findings. JAMA
2002; 287:2140-1
Carulli DT. Abnormal cervical cytology: new names,
familiar smears. J Am Acad Nurse Pract. 2003; 15 (10):444-449.
Munoz N. Human papillomavirus and cancer: the epidemiological
evidence. J Clin Virol 2000; 19 (1-2):1-5
Iftner T, Holz B. HPV und Zervixkarzinom - Fragen
und Antworten. Frauenarzt 2002; 43 (4): 438-441
Nagai Y, Maehama T, Asato T, Kanazawa K. Persistance
of human papillomvirus infection after therapeutic conisation
for CIN3: is it an alarm for disease recurrence? Gynecol Oncol
2000; 79 (2): 294-9
van der Graaf Y, Molijn A, Doornerwaard H, quint W, van
Doorn LJ, van den Tweel J. Human Papillomavirus and the
Long-term Risk of Cervical Neoplasia. Am J Epidemiol 2002;
156: 158-164
Friedman EA, Borten M, Chapin DS. Diagnostische und
therapeutische Entscheidungen in der Gynäkologie, Ferdinand
Enke Verlag Stuttgart 1991
Göretzlehner G, Lauritzen C. Praktische Hormontherapie
in der Gynäkologie. Walter de Gruyter, Berlin New York 1995
Graf M. Physiologie des Menstruationszyklus. Gynäkologe
1996; 29:70-83
Grünberg W. Kinder und Jugendgynäkologie. Öst Ärztezt
1998; 27-31
Heinz M. Hormontherapie bei Mädchen. T&E Gynäkologie,
1998; 216-220
Kaiser R. Diagnose und Therapie von Zyklusstörungen
bei Jugendlichen. Frauenarzt; 1990; 31(6): 555-557
Heinz M. Kinder- und Jugendgynäkologie in Sprechstunde
und Klinik. Deutscher Ärzte Verlag Köln, 1994
Graf M, Distler W. Pathogenese der gestörten Ovarialfunktion.
Gynäkologe 1996; 29:259-267
Foth D. Hormonelle Therapie von Blutungsstörungen.
Frauenarzt, 2003; 44 (7): 746-750
Rowland AS, Baird DD, Long S, Wegienka G, Harlow SD, Alavanja
M, Sandler DP. Influence of Medical Conditions and Lifestyle
Factors on the Menstrual Cycle. Epidemiology 2002; 13 (6):
668-674
|
